Terms: = Liver cancer AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1 AND Prognosis
75 results:
1. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
Yang LM; Wang HJ; Li SL; Gan GH; Deng WW; Chang YS; Zhang LF
World J Gastroenterol; 2024 Mar; 30(11):1533-1544. PubMed ID: 38617449
[TBL] [Abstract] [Full Text] [Related]
2. Smart glypican-3-targeting peptide-chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma.
Fang Y; Ma H; Zhang X; Zhang P; Li Y; He S; Sheng C; Dong G
Eur J Med Chem; 2024 Jan; 264():116047. PubMed ID: 38118394
[TBL] [Abstract] [Full Text] [Related]
3. Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract] [Full Text] [Related]
4. Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.
Li N; Dong T; Wang P; Li Q; Nie F
Clin Hemorheol Microcirc; 2023; 85(4):407-420. PubMed ID: 37638421
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological features and differential diagnosis of gastric metastases.
Chen W; Liu C; Liu Y; Yuan J; Wang Z
World J Surg Oncol; 2023 Aug; 21(1):258. PubMed ID: 37608278
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of S100A4 and Glypican-3 in hepatocellular carcinoma in cirrhotic HCV patients.
El-Bendary M; Farid K; Arafa M; Elkashef W; Abdullah T; El-Mesery A
J Egypt Natl Canc Inst; 2023 Aug; 35(1):26. PubMed ID: 37599312
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological characteristics of gastric adenocarcinoma with enteroblastic differentiation and gastric adenocarcinoma with enteroblastic marker expression.
Abe D; Akazawa Y; Yatagai N; Hayashi T; Ueyama H; Mine S; Fukunaga T; Nagahara A; Yao T; Saito T
Virchows Arch; 2023 Sep; 483(3):405-414. PubMed ID: 37581693
[TBL] [Abstract] [Full Text] [Related]
8. Quantitative image features of gadoxetic acid-enhanced MRI for predicting glypican-3 expression of small hepatocellular carcinoma ≤3 cm.
Dong SY; Sun W; Xu B; Wang WT; Yang YT; Chen XS; Zeng MS; Rao SX
Clin Radiol; 2023 Oct; 78(10):e764-e772. PubMed ID: 37500336
[TBL] [Abstract] [Full Text] [Related]
9. Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients.
Mauro M; Ugo P; Walton Z; Ali S; Rastellini C; Cicalese L
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446098
[TBL] [Abstract] [Full Text] [Related]
10. [The clinical value of serum gpc3 level in predicting recurrence of patients with primary hepatocellular carcinoma].
Zhang PR; Ma XL; Guo L; Lu RQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jun; 57(6):885-890. PubMed ID: 37357208
[No Abstract] [Full Text] [Related]
11. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
Cheng F; Hansson VC; Georgolopoulos G; Mani K
Oncotarget; 2023 Mar; 14():219-235. PubMed ID: 36944188
[TBL] [Abstract] [Full Text] [Related]
12. MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities.
Sequera C; Grattarola M; Holczbauer A; Dono R; Pizzimenti S; Barrera G; Wangensteen KJ; Maina F
Cell Death Dis; 2022 Nov; 13(11):994. PubMed ID: 36433941
[TBL] [Abstract] [Full Text] [Related]
13. Diagnostic and Prognostic Value of Isolated and Combined MCM3 and Glypican-3 Expression in Hepatocellular Carcinoma: A Novel Immunosubtyping Prognostic Model.
Mohamed AS; Abd El Hafez A; Eltantawy A; Mahfouz M
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):694-702. PubMed ID: 36350065
[TBL] [Abstract] [Full Text] [Related]
14. Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma.
Pallerla SR; Hoan NX; Rachakonda S; Meyer CG; Van Tong H; Toan NL; Linh LTK; Giang DP; Kremsner PG; Bang MH; Song LH; Velavan TP
BMC Med Genomics; 2022 Nov; 15(1):235. PubMed ID: 36345011
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value and morphological findings of overexpression of glypican-3 in hepatocellular carcinoma.
Karaoğullarindan Ü; Gümürdülü Y; Üsküdar O; Odabaş E; Güler HS; Tozluklu N; Bağir E; Kuran S
Eur J Gastroenterol Hepatol; 2023 Jan; 35(1):89-93. PubMed ID: 36165051
[TBL] [Abstract] [Full Text] [Related]
16. Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging.
Chen Y; Qin Y; Wu Y; Wei H; Wei Y; Zhang Z; Duan T; Jiang H; Song B
Front Immunol; 2022; 13():973153. PubMed ID: 36091074
[TBL] [Abstract] [Full Text] [Related]
17. Both the serum AFP test and AFP/gpc3/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma.
Wang B; Xie Y; Zheng L; Zheng X; Gao J; Liu X; Yuan Y; Li Z; Lu N; Xue L
BMC Gastroenterol; 2021 Oct; 21(1):408. PubMed ID: 34706681
[TBL] [Abstract] [Full Text] [Related]
18. High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice.
Chu Q; Mu W; Lan C; Liu Y; Gao T; Guan L; Fang Y; Zhang Z; Liu Y; Liu Y; Zhang N
Int J Nanomedicine; 2021; 16():4161-4173. PubMed ID: 34168446
[TBL] [Abstract] [Full Text] [Related]
19. A Clinicopathological Study of Young-onset Hepatocellular Carcinoma.
Au KY; Chan KK; Lo RC
Anticancer Res; 2021 Jun; 41(6):2933-2944. PubMed ID: 34083284
[TBL] [Abstract] [Full Text] [Related]
20. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.
Wang JY; Wang XK; Zhu GZ; Zhou X; Yao J; Ma XP; Wang B; Peng T
BMC Cancer; 2021 Apr; 21(1):462. PubMed ID: 33902495
[TBL] [Abstract] [Full Text] [Related]
[Next]
